Global Ovulation Inducing Drugs Market, By Drug Class (Hormones, Therapeutics Drugs), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Ovulation Inducing Drugs Market Analysis and Size
The global ovulation inducing drugs market is expected to witness significant growth during the forecast period. Changing lifestyle, delayed pregnancy, adverse medicinal effects, and comorbidities led to the higher adoption of in vitro fertilization (IVF) or assisted reproductive treatments worldwide. Physicians insist on removing a maximum number of eggs because of low volatility and high failure rates in fertilization and other IVF procedures. Numerous medications, including pharmaceutical preparations and hormones, are administered to induce ovulation and upsurge egg count. Several developing markets and huge R&D investments are the factors responsible for the growth of this market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the g global ovulation inducing drugs market in the forecast period 2022-2029. The expected CAGR of global ovulation inducing drugs market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 3.82 billion in 2021, and it would grow upto USD 6.1 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Anovulation is a type of infertility condition wherein the follicles in the ovary do not mature and release eggs for which ovulation treatment is given. Ovulation induction is a kind of treatment for this condition. Many drugs that fuel the ovary to develop and release eggs can be used to persuade ovulation. Obesity, stress, diabetes, poly cystic ovarian syndrome (PCOS), smoking, and other lifestyle disorders and unhealthy diets are rising, resulting in higher demand for ovulation-inducing drugs.
Ovulation Inducing Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Hormones, Therapeutics Drugs), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Abbvie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Serum Institute of India Pvt. Ltd (India)
|
|
Market Opportunities
|
|
Global Ovulation Inducing Drugs Market Dynamics
Drivers
- Growing Research Developments
There has been rising developments in this disease area, boosting the market growth. For instance, Ferring Pharmaceuticals, a biopharmaceutical corporation, purchased the commercialization rights of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd in 2019 for an undisclosed amount. Ferring Pharmaceuticals aims to enlarge its portfolio of reproduction-related medicines as a result of the acquisition. The FDA approved Ganirelix Acetate Injection in 2018 for regulating premature luteinizing hormone (LH) levels in women undergoing fertility treatment. This boosts the market growth.
- Rising Demand for Therapeutic Drugs
Clomiphene or Clomid tablets are the most extensively used medications to treat these patients. Clomiphene or Clomid tablets fuel follicles and thus egg development by growing the pituitary gland's production of follicle-stimulating hormone (FSH). Clomiphene citrate is preferred more because it is inexpensive, effective when taken orally, has lesser side effects, and is comparatively safe for the foetus.
Opportunities
- Increasing Infertility Cases
Per the records of the Centers for Disease Control and Prevention (CDC) in 2019, infertility affects around 10% of women between the ages of 15 to 44 years in the US. Additionally, in 2019, in India, 10% to 15% of couples in reproductive age group suffer from infertility. Henceforth, the increasing cases of infertility worldwide is growing the demand for ovulation inducing drugs.
- Increasing Demand for Retail Pharmacies
The rise in the number of ovulation inducing therapeutics being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Ovulation Inducing Drugs
There are various side effects of infertility drugs, such as nausea, upper respiratory tract infection, headache, abdominal tenderness, mood swings, acne, breast tenderness, sinus inflammation, weight gain, pelvic discomfort, unexplained bleeding or spotting, vomiting, injection site pain, dizziness, and Ovarian Hyper-Stimulation Syndrome, redness which are restraining the market growth of ovulation-inducing drugs.
- High Cost
The high cost of IVF procedure and low success rates are the primary factors restraining the global ovulation-inducing drug market.
This global ovulation inducing drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ovulation inducing drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Ovulation Inducing Drugs Market Scope
The global ovulation inducing drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Hormones
- Follicle stimulating hormone (FSH)
- Human menopausal gonadotropin (hMG)
- Human chorionic gonadotropin (hCG)
- Therapeutics Drugs
- Gonadotropin releasing hormone (GnRH) agonists
- GnRH antagonists
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Ovulation Inducing Drugs Market Regional Analysis/Insights
The global ovulation inducing drugs market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global ovulation inducing drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global ovulation-inducing drugs market throughout the forecasted period due to the rise cases of infertility and the increase in awareness about the ovulation inducing drugs as well as advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase in government initiatives and developing healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Ovulation Inducing Drugs Market Share Analysis
The global ovulation inducing drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global ovulation inducing drugs market.
Key players operating in the global ovulation inducing drugs market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Abbvie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Serum Institute of India Pvt. Ltd (India)
SKU-